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ABSTRACT
Objective: This study aimed to assess the knowledge of undergraduate students of MAHSA University on human papillomavirus (HPV) vaccination.
Methods: The cross-sectional study was conducted using a self-administered questionnaire among 350 local undergraduate students recruited by 
convenience sampling. The survey was conducted in English and consisted of questions on demographic data and 14 questions on knowledge toward 
HPV vaccination. Verbal consent was obtained from the participants beforehand, and their participation was voluntary and anonymous.
Results: The participants have scored below average (6.09±3.39) for knowledge on HPV vaccines with a significant difference in terms of age, gender, 
and program of the study. Students from medicine, dentistry, and biomedical science tend to have better mean knowledge score (7.39±2.99) with 25% 
scored 10 and above. The non-health-care students showed insignificant lower mean knowledge score of 4.17±2.06, respectively.
Conclusion: This study has demonstrated moderate level HPV vaccine knowledge toward HPV vaccination among university students with majority 
posed background of health-related knowledge.
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INTRODUCTION
Human papillomavirus (HPV) is the most common viral infection of 
the reproductive system, and it is one of the most common sexually 
transmitted diseases [1,2]. Approximately 99% of the cervical cancer 
cases are contributed by HPV infection [3]. Common high-risk HPV 
strains, which are HPV 16 and 18, contribute 70% of cervical cancers 
and also cancers of anus, vagina, vulva, penis, and head and neck 
cancers [4]. There is less probability from low-risk HPV strains to cause 
cancer; however, HPV strains 6 and 11 can contribute 90% occurrence 
of genital warts [5].
Administration of prophylactic vaccine and elimination of sexual risk 
factor are the primary prevention of HPV infection [6]. The Food and 
Drug Administration has approved three vaccines for preventing HPV 
infections, which are Gardasil® (quadrivalent HPV vaccine), Gardasil® - 9 
(nanovalent HPV vaccine), and Cervarix® (bivalent HPV vaccine) and 
administered through 3 injections intramuscularly. According to the 
National Cancer Institute high-risk HPV strains, HPV 16 and 18 can 
be prevented with these three HPV vaccines. The Advisory Committee 
on Immunization Practices (ACIP) recommended the routine use of 
Gardasil® in females aged 11 or 12 years old [7,8].
Shafiee, in his study, pointed out that 30–60% of all sexually active 
adults will acquire HPV infection at some point in their lives and highest 
incidence occurred among adult aged between 18 and 28 years old [10]. 
Administration of HPV vaccine after first sexual intercourse reported 
lessen efficacy of HPV vaccine [11]. Persistent infection with high-risk 
HPV genotypes leads to cancers though most of the HPV infections are 
self-limiting. Another study showed that younger age women, use of 
contraceptives, alcohol drinking, and smoking have a higher risk of HPV 
infection [12].
In Malaysia, the Ministry of Health (MOH) has implemented the 
National HPV vaccination program since 2010, which targeted for Form 
1 female students and free for three complete doses [13]. However, 
there are limited studies about HPV vaccine knowledge and its attitude 
among university students which include male and female in Malaysia. 
The studies carried out in Malaysia previously include a population of 
non-healthcare university students, mother, secondary school girls, and 
female adults [10,14-16]. This study aims to determine the knowledge 
of HPV vaccination among MAHSA University students.
METHODS
The questionnaires were adapted from two studies conducted previously 
on two different populations [10,17]. Questions on demographic 
profile were outlined based on literature review of numerous similar 
studies. The HPV vaccination knowledge statements were consisted of 
15 questions with the options of true, false, and unsure. In knowledge 
section, one point was given to a correct answer by respondents. 
The knowledge score for the respondents was categorized into poor, 
moderate, and good knowledge. The questionnaire was pilot tested and 
resulted in Cronbach’s alpha of 0.619.
The questionnaires were made available to all MAHSA university 
students studying bachelor degree regardless of age. Only Malaysian 
nationalities were included. Bachelor degree students who were not 
available in the campus and in semester break were excluded from the 
study.
The completed questionnaires were analyzed using the SPSS Statistical 
software version 22. Descriptive statistics were used to analyze the 
frequency, percentage, and mean of the data. Independent t-test and 




From the data collected from university registry office, 1757 Malaysian 
students were registered for bachelor’s studies regardless of year and 
courses during the time of this study. A number of 350 questionnaires 
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were distributed randomly in classes, libraries, and university cafes to 
meet the minimum sample size. The demographic profile is tabulated 
in Table 1. Two-thirds of the respondents were female and aged 18–
23 years old. Almost all respondents were from health-care-related 
courses (90%).
Knowledge on HPV vaccine brand name
A huge amount of 84.6% (n=296) responded positive when asked 
on the availability of HPV vaccines in Malaysia regardless of courses 
or gender. They were unsure on the brand name, but they knew the 
MOH campaign on HPV vaccination program which started in 2010. 
The number of respondents recognized Cervarix® as HPV vaccine was 
higher than Gardasil®, with 20.3% and 4.7%, respectively. Only 2.4% 
replied that both brands are available in Malaysia which is true.
Despite major campaign by the ministry to provide free school-based 
vaccination to Form 1 secondary school students (irrespective of age), 
34.5% of participants believe that the vaccine is only to be taken at 
18 years old and above and 26.4% of respondents were uncertain on 
the recommended age (Table 2). A smaller number of respondents 
knew that HPV vaccination is available to both genders (19.3%) since 
the free vaccination was only delivered for Malaysian women aged 18–
26. More than half (58.5%) recognizes the need to take three injections 
of the vaccine over 6 months’ duration.
Knowledge on HPV vaccine uses
An analysis of correct responses to the survey questionnaires was 
performed (Table 2). A vast majority knew that HPV vaccines protect 
against cervical cancer, but only 38.5% noticed that HPV vaccination 
only protects against certain strains of virus that causes cervical cancer. 
Moreover, similar numbers of participants were unsure on numerous 
strains of HPV. About 21.3% of respondents thought that HPV 
vaccination acts as preventive measures against all sexually transmitted 
infections (STI), whereas 46.3% that aware of the HPV vaccination is 
only for the most common STI.
Nearly half (44.6%) knew that this vaccine will protect them from 
genital warts, but 17.9% falsely believed the vaccine as genital warts 
treatment. Only 27% and 23% knew that HPV vaccination will not treat 
genital warts and genital herpes, respectively. Only few respondents 
(47%) noticed that HPV vaccination is best taken before first sexual 
activities and aware that the effects of vaccination pre- and post- sexual 
activities were unsimilar. The participants (53.4%) knew that the HPV 
vaccination is important to women with one sexual partner as well as 
for women with multiple partners.
A higher percentage (42.9%) of respondents were uncertain that 
women previously vaccinated further pap smear and 48.3% realized 
that pap smear test acts as extra protective measures in addition to HPV 
vaccination since it acts as early detection or screening procedure of 
cervical cancer.
Knowledge scores were reported in mean with a range between 0 
and 15 (Table 3). Interestingly, despite the high percentage of positive 
response toward HPV vaccination, only 16.6% of 296 participants 
showed a good knowledge score with one-third poor score. The mean 
score was moderate with 6.09±3.39 (mean±standard deviation [SD]).
Three sociodemographic variables (age, gender, and courses) were 
analyzed in determining their association that could influence their 
knowledge score on HPV vaccination (Table 4). There was a good 
knowledge score with an increase in age. A significant difference was 
found in knowledge scores between genders despite both genders 
displayed the moderate score of 5.81±3.70 and 6.82±3.58 for male and 
Table 1: Demographic profile of respondents (n=350)


















Biomedical science 58 (16.6)
Physiotherapy 55 (15.7)
Medical imaging 21 (6.0)
Environmental health 4 (1.1)
Engineering 9 (2.6)
Business 22 (6.3)
Table 2: Knowledge of the respondents toward HPV vaccination (n=296)
Statements Answer n (%)
Answer correctly Answer incorrectly Unsure 
HPV vaccine protects against cervical cancer. True 226 (76.4) 2 (0.7) 68 (23.0)
HPV vaccine protects against all types of the virus that causes cervical 
cancer.
False 114 (38.5) 68 (23.0) 114 (38.5)
HPV vaccine protects against all sexually transmitted infections. False 137 (46.3) 63 (21.3) 96 (32.4)
HPV vaccine can only be taken after the age of 18 years old. False 116 (39.2) 102 (34.5) 78 (26.4)
HPV vaccine is currently available to both men and women. True 57 (19.3) 127 (42.9) 112 (37.9)
HPV vaccination is taken as three injections over 6 months. True 173 (58.5) 19 (6.4) 104 (35.1)
HPV vaccine can treat genital warts. False 80 (27.0) 51 (17.2) 165 (55.7)
HPV vaccine offers protection against genital warts. True 132 (44.6) 27 (9.1) 137 (46.3)
HPV vaccine does not protect against genital herpes. True 68 (23.0) 66 (22.3) 162 (54.7)
Women who receive HPV vaccine need less frequent pelvic examination. False 120 (40.5) 34 (11.5) 142 (48.0)
Women who receive HPV vaccine do not have to get Pap smear. False 143 (48.3) 26 (8.8) 127 (42.9)
HPV vaccine is best taken before starting to have sexual activities. True 139 (47.0) 59 (19.9) 98 (33.1)
HPV vaccines have the same effect whether the female takes it before or 
after being infected with HPV.
False 141 (47.6) 22 (7.4) 133 (44.9)
HPV vaccine is only important for women with more than one sexual 
partner.
False 158 (53.4) 53 (17.9) 85 (28.7)
HPV: Human papillomavirus
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female respondents, respectively. Results shown in Table 4 were similar 
between three health-care courses (medicine, dentistry, and biomedical 
science) with an average knowledge score of 7.39±2.99 (n=168) and 
medical imaging students (6.27±2.67; n=15) showed slightly higher 
knowledge score compared to pharmacy students (5.79±3.10; n=48). 
Participants from non-health-care courses showed poor-to-moderate 
knowledge score of  4.17±2.03 (n=23).
DISCUSSION
This study assessed on knowledge of MAHSA university students on 
HPV vaccination by random selection. In this study, the respondents 
were mainly made up from the age of 21 to 23 years old (62.9%). 
The young adult is the main concern in this study as more than half 
of the sexual-transmitted disease-infected population are from the age 
range of 15 to 24 years old [18]. The awareness level of 84.6% was 
observed in this study which was similar to that reported by Blodt and 
his research group Blödt et al. [19]. The percentages reported by the 
previous studies conducted in Malaysia were as low as 7.8% and up to 
76.3% [3,10,15,20].
There was moderate knowledge mean score seen in this study which 
was similarly noted among pre-university students [1 ]. Most of the 
students (76.4%) knew the purpose of HPV vaccination which is similar 
to the other two studies conducted in Malaysia with 67.9% and 73.2%, 
respectively [1,10]. A low number of 23% of students were seen to be 
unaware of the function of HPV vaccination despite the HPV school-
based vaccination program was launched in 2010.
Although 44.6% knew that the vaccine also protects against genital 
warts and it was higher compared to study done among Belgian 
students (19.4%) [21] and Sadry research group [22], the percentage 
was expected to be higher since most of the respondents (92%) were 
from health-care-related courses. HPV vaccination is well known 
for protection against cervical cancer compared to genital warts and 
genital herpes though both are caused by certain strains of HPV [22].
Higher awareness of cervical cancer protection by HPV vaccine is due 
to common non-technical term for HPV vaccines which is “the cervical 
cancer vaccine” which targeted to young women at the aged 26 and 
below rather than for men [15]. With regard to vaccination among men, 
42.9% of students’ misunderstood that the uses of HPV vaccine are only 
for women, and it has been demonstrated that Gardasil® was shown to 
prevent cancer and HPV-related diseases in men [23].
Condoms may lower the chances of suffering HPV for sexually active adults, 
but it does not eliminate the risk which not gives a full protection [24].
In this study, almost half of the participants answered correctly that 
the course of HPV vaccination is three injections over 6 months and 
approximate number unsures with this statement. Similar pattern 
observed among female students in Lebanon and lower percentage 
(36.2%) in Penang [3,17]. ACIP initiated two doses of HPV vaccination 
for girls and boys between ages 9 and 14 years and recommended three 
doses for 15–26 years old, whereas complete regimen of 3 doses within 
6 months duration in Malaysia [1,9].
Nearly half of the respondents demonstrated good understanding 
that full benefits of the vaccination are available only for those who 
taken it before their first sexual encounter. Since HPV infection is 
transmitted directly, the onset of infection may start immediately after 
sexual intercourse [5]. However, a positive result was shown in studies 
conducted among college students in Lebanon and Belgium with higher 
percentages of 66% and 83%, respectively [17,21].
The participants (53.4%) knew that the HPV vaccination is important to 
women with one sexual partner as well as for women with multiple partners. 
The reported positive percentage of respondents’ knowledge was lower 
compared to result in a study done in Toronto that most of respondents 
(87.8%) aware that the number of sexual partners is not a determinant 
factor for HPV vaccination [22]. Adequate information regarding the 
benefits of it despite sexual inactive should be addressed as it could be one 
of the main barriers for unintended of vaccination [2]. Moreover, having less 
number of sexual partner helps in reducing the risk of HPV infection [15].
Furthermore, approximately half of the respondents knew the need 
of Pap smear screening even after HPV vaccination. However, similar 
numbers of respondents (42.9%) hesitate that pap smear could 
provide extra benefit post vaccination. In a study by Wong and Sam 
among female university students, more than half (57.2%) heard of 
pap smear test, but only minority of them could identify the use of pap 
smear [20]. Thus, misinformation has led to a lower rate of cervical 
cancer screening among vaccinated female population compared to 
unvaccinated group [25,26]. It is critical as HPV vaccination together 
with regular Pap smear test effective in preventing mortality and 
morbidity brought by HPV infections [21].
Knowledge scores among health related students were found slightly 
higher though moderate compared to non-health-related programmes. 
Similar results were found in college female students in Lebanon [17]. 
Among all the programmes involved in this study, students from 
physiotherapy studies showed the lowest mean knowledge 
score [2.21±2.37]. This may be due to syllabus learnt which focus on 
human anatomy, rather than physiology. In a study run in obstetrics 
clinic, the knowledge of HPV vaccines and HPV immunization program 
was significantly associated with the level of education and ages [14].
CONCLUSION
This study has demonstrated moderate level HPV vaccine knowledge 
toward HPV vaccination among university students with majority pose 
background of health-related knowledge. Besides, the survey was a 
cross-sectional study instead of longitudinal, and hence, unable to 
provide information on changes of findings over time. Knowledge is 
likelihood to associate with attitude toward HPV vaccination, and thus, 
it is important to stress on the dissemination of information related to 
HPV vaccination among young adults.
Table 3: Knowledge mean score among participants
Knowledge 
mean score
Poor 0‑4 Moderate 5‑9 Good 10‑15
Frequency (%) 96 (32.4) 151 (51.0) 49 (16.6)
One point was given to correct answer for each question. The knowledge score 
was categorized into poor, moderate, and good knowledge
Table 4: Correlations between knowledge mean score and 
sociodemographic variables
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